Hypertensive Herzkrankheit

Zusammenfassung

Erhöhter Blutdruck, gesteigerte Aktivität des sympathischen Nervensystems und des Renin-Angiotensin-Aldosteron-Systems, oxidativer Stress und Inflammation sind bedeutsam in der Pathogenese einer hypertensiven Herzkrankheit.

Die transthorakale Echokardiografie ist die Methode der Wahl zur Diagnose und Verlaufsbeobachtung der unterschiedlichen funktionellen und morphologischen Veränderungen des Herzens bei HHK.

Eine Koronarangiografie schließt eine koronare Herzerkrankung mit hoher Sicherheit aus. Nicht invasive nuklearkardiologische Verfahren erfassen die myokardiale Perfusion auf zellulärer Ebene und spiegeln die gesamte Perfusionsstrecke (Makro- und Mikrozirkulation) wieder.

Konsequente nicht medikamentöse und medikamentöse Therapien führen zur Normotonie und zum positiven Remodeling des Herzens bei HHK.

Abstract

Elevated blood pressure, increased activity of the sympathetic nervous system and the renin-angiotensin-aldosteron system, as well as inflammation are important factors in the pathogenesis of hypertensive heart disease.

Transthoracic echocardiography is the method of choice in the diagnosis and follow-up of functional and morphological cardiac changes in hypertensive heart disease.

Coronary angiography safely excludes the presence of coronary heart disease. By means of noninvasive molecular imaging myocardial perfusion at cellular level as well as the complete macrocirculation and microcirculation are visible.

Consistent drug therapy and lifestyle modification lead to blood pressure control and positive cardiac remodelling in patients with hypertensive heart disease.

Schlüsselwörter

hypertensive Herzkrankheit - linksventrikuläre Hypertrophie - Fibrose - diastolische Dysfunktion - systolische Dysfunktion - Herzrhythmusstörungen - Remodeling des Herzens

Key words

hypertensive heart disease - left ventricular hypertrophy - fibrosis - diastolic dysfunction - systolic dysfunction - arrhythmias - cardiac remodelling

• Literatur

• 1 Horacek M et al. Prävalenz der arteriellen Hypertonie in der westdeutschen Bevölkerung. Herz 2012; 37: 721-727
• 2 Cuspidi C et al. Prevalence of left-ventricular hypertrophy in hypertension: an update review of echocardiographic studies. J Hum Hypertens 2012; 26: 343-349
• 3 Lawes CM et al. Global burden of blood-pressure-related disease. Lancet 2001; 371: 1513-1518
• 4 Masoudi FA et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41: 217-223
• 5 Aurigemma GP et al. Clinical practice. Diastolic heart failure. N Engl J Med 2004; 351: 1097-1105
• 6 Diamond JA et al. Hypertensive heart disease. Hypertens Res 2005; 28: 191-202
• 7 Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (AH) – possible therapeutic perspectives. J Am Soc Hypertens 2011; 5: 449-455
• 8 Harada M et al. Significance of ventricular myocytes and nonmyoctes interaction during cardiocyte hypertrophy: evidence of endothelin-1 as a pacrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997; 96: 3737-3744
• 9 Molkentin JD et al. A calcineurin-dependent transcription pathway for cardiac hypertrophy. Cell 1998; 93: 215-228
• 10 Zhou N et al. Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. Biochem Biophys Res Commun 2010; 397: 263-269
• 11 Hsueh WA et al. Integrins, adhesion, and cardiac remodeling. Hypertension 1998; 93: 215-228
• 12 Devereux RB et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regulary recurring stress. Circulation 1983; 68: 470-476
• 13 Mancia G et al. ESH-ESC Practical Guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 2007; 25: 1751-1762
• 14 Deutsche Hochdruckliga e.V.. DHL Leitlinien zur Behandlung der arteriellen Hypertonie 2008. Im Internet: http://www.hochdruckliga.de Zugriff: 14.04.2013
• 15 Lüders S et al. 24-h-Langzeitblutdruckmessung (ABDM). Statement der Deutschen Hochdruckliga e.V. DHL® (Deutsche Gesellschaft für Hypertonie und Prävention), Sektion Hochdruckdiagnostik. Der Kardiologe 2013; 7
• 16 Buck T et al. Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol Suppl 2009; 4: 3-51
• 17 Higgins CB. Which standard has the gold?. J Am Coll Cardiol 1992; 19: 1608-1609
• 18 Maceira AM et al. Normalized left ventricular systolic and diastolic function by steady state free precession Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson 2006; 8: 417-426
• 19 Prinz C et al. Echocardiographic particle image velocimetry in a patient with servere diastolic dysfunction. Eur Heart J 2013; 34: 450
• 20 Edelmann F et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011; 58: 1780-1791
• 21 Holland DJ et al. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol 2011; 57: 1676-1686
• 22 Murray JJV et al. ESC Guidelines for the diagnostic and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847
• 23 Adamu U et al. Stress/rest myocardial perfusion scintigraphy in patients without significant coronary artery disease. J Nucl Cardiol 2010; 17: 38-44
• 24 Le Heuzey JY et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for arterial fibrillation. Am J Card 2010; 105: 687-693